Abstracts tagged "Inflammation"

Abstract Number: 1736 • ACR Convergence 2025
Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Kevin Burt¹, Sanique South², Natalie Adamczyk³, Shingo Ishihara³, Vu Nguyen⁴, Robert Mauck⁴, Anne-Marie Malfait⁵, Timothy Griffin⁶, Rachel Miller⁷ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Oregon, Eugene, ³Rush University, Chicago, ⁴University of Pennsylvania, Philadelphia, ⁵Rush University, Oak Park, IL, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Soluble CD14, a co-receptor of inflammatory toll-like receptor signaling that is produced primarily by monocytes/macrophages, is present in synovial fluid in patients with OA…
Abstract Number: 1325 • ACR Convergence 2025
Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee¹, Punyasha Roul², Grant Cannon³, Gary Kunkel⁴, Beth Wallace⁵, Isaac Smith⁶, John Richards⁷, Katherine Wysham⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Joshua Baker¹³, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁵Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁶Duke University Hospital, Durham, NC, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: The mechanisms of heart failure (HF) risk in RA remain incompletely understood. HF with preserved ejection fraction (HFpEF) is over-represented in RA, which may…
Abstract Number: 1114 • ACR Convergence 2025
Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Mei-Feng Shi¹, Fang-Shu Zou¹, Xiao-Na Ma¹, Wei Feng¹, Yi-Fang Zhang², Chang-Song Lin¹, Min-Ying Liu² and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic)
Background/Purpose: Methotrexate (MTX) is a first-line treatment for autoimmune diseases, including rheumatoid arthritis (RA). Its potential risk of inducing type 2 diabetes mellitus (T2DM) remains…
Abstract Number: 0654 • ACR Convergence 2025
Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Ed Vital¹, Benni Vargas², Julie Rae², Tracey Wang³, Jason Hackney², Cary Looney⁴, William Pendergraft², Liz Lightstone⁵, Brad Rovin⁶, Richard Furie⁷ and Harini Raghu², ¹University of Leeds, Leeds, England, United Kingdom, ²Genentech, Inc., South San Francisco, CA, ³Hoffmann-La Roche Ltd, Missssauga, ON, Canada, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁵Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁶The Ohio State University, Columbus, OH, ⁷Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Lupus nephritis (LN) is characterized by kidney inflammation. B cells play a central role in LN pathogenesis and type I interferon (IFN-I) pathway activation…
Abstract Number: 0463 • ACR Convergence 2025
Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Solana Cushing¹, Susan Goodman², Michael Parides¹, Hadeel Abdul-Rehman¹, Daniel Ramirez², Edward DiCarlo², Kristine Carandang³, Renee Davis⁴, Rebecca Blank⁵, Laura Donlin¹, Anna Helena Jonsson⁶, Amit Lakhanpal², Bella Mehta⁷, Dana Orange⁸ and Melanie smith², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, ⁴New York, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶University of Colorado School of Medicine, Aurora, CO, ⁷Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ⁸The Rockefeller University, New York, NY
Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
Abstract Number: 0134 • ACR Convergence 2025
Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
NaveenKumar Somanathapura¹, Thalia Newman¹, Chao Liu², Srilakshmi Yalavarthi³, Cyrus Sarosh⁴, Jacqueline Madison¹, Ajay Tambralli¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Superior Charter Twp, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, ⁴University of Michigan, Temperance, MI
Background/Purpose: Emerging evidence implicates neutrophil activation and neutrophil extracellular trap (NET) formation (i.e., NETosis) in amplifying APS-associated thromboinflammation. Gasdermin D (GSDMD), a substrate of inflammatory…
Abstract Number: 0061 • ACR Convergence 2025
IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
Shinjiro Kaieda¹, Suzuna Sugi¹, Takuma Koga², Takashi Kinoshita¹ and Tomoaki Hoshino¹, ¹Kurume university School of Medicine, Kurume, Japan, ²Kurume Universty School of Medicine, Kurume, Japan
Background/Purpose: IL-22 is a key cytokine involved in modulating tissue responses during inflammation and is markedly upregulated in inflammatory diseases, such as psoriasis, inflammatory bowel…
Abstract Number: 2466 • ACR Convergence 2025
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Richard Furie¹, Neel Anand², Shraddha Desai³, Eric Lowe⁴, Tony Muchamuel³, Kiruthi Palaniswamy², Rachel Peterson², Kathryn Ray², Zung To², Jennifer Whang² and Richard Leff⁵, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Kezar Life Sciences, Inc, South San Francisco, CA, ³Kezar Life Sciences, Inc, South San Francisco, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Richard L Leff MD LLC, Chadds Ford, PA
Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
Abstract Number: 2044 • ACR Convergence 2025
Infections and Associated Mortality in VEXAS Syndrome: A Systematic Review and Meta-Analysis
Oyku Zeynep Avarbek¹, Ozlem Arikan², Aysu Tatari³, Furkan Ak⁴, Bengisu Gur⁵, Sinem Nursel Duzenci⁶, Yasin Taha Tuncar⁷, Mustafa Sivri⁸, Mustafa Ovayolu⁹ and Miray Kurtca¹⁰, ¹Bezmialem Vakif University, Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ²Istanbul Aydin University, Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ³Pamukkale University, Faculty of Medicine, Denizli, Türkiye, Denizli, Turkey, ⁴Sofia University St. Kliment Ohridski, Faculty of Medicine, Sofia, Bulgaria, Sofia, Bulgaria, ⁵Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye, Istanbul, Turkey, ⁶Balikesir University, Faculty of Medicine, Balikesir, Türkiye, Balikesir, Turkey, ⁷Akdeniz University, Faculty of Medicine, Antalya, Türkiye, Istanbul, Turkey, ⁸Gazi University, Department of Emergency Medicine, Ankara, Türkiye, Ankara, Turkey, ⁹Hacettepe University, Faculty of Medicine, Ankara, Türkiye, Ankara, Turkey, ¹⁰Richmond University Medical Center, Department of Internal Medicine, Staten Island, NY
Background/Purpose: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a late-onset, monogenic autoinflammatory disorder driven by somatic mutations in the UBA1 gene of hematopoietic…
Abstract Number: 1735 • ACR Convergence 2025
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Elise Herardot¹, Nadine Soliman¹, Audrey Pigenet¹, Ilana Slotine¹, Anni Herranan², Samia Bahieddine¹, Jean-Baptiste Fini², Olivier Tabary¹, Adeline Cambon³, Xavier HOUARD⁴, Francis BERENBAUM⁵, SELLAM JEREMIE⁶ and Alice Courties⁷, ¹Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, Paris, France, ²UMR ⁷²²¹, Phyma, CNRS–Muséum National d’Histoire Naturelle, Sorbonne Université, ⁷⁵⁰⁰⁵ Paris, France, Paris, France, ³Department of Orthopedic, Trauma and Hand Surgery, Hôpital Saint-Antoine, Sorbonne University, ¹⁸⁴ Rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France, ⁴Centre de Recherche Saint-Antoine, UMR_S⁹³⁸ INSERM /Sorbonne Université, Paris, France, PARIS, France, ⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ⁶Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹², Paris, France / Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France
Background/Purpose: Osteoarthritis (OA) affects over 590 million individuals globally. Epidemiological data suggest that exposure to environmental pollutants, particularly endocrine-disrupting chemicals (EDCs) such as phthalates, PFAS,…
Abstract Number: 1315 • ACR Convergence 2025
High-resolution thermography and Artificial Intelligence to evaluate and classify Rheumatoid Arthritis
Kale Mayor¹, Joey Mercier¹, Yuxi Long², David Robinson¹, Pingzhao Hu², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Western University, London, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune polyarthritis that typically affects the small joints of the hands and feet. While imaging modalities such as ultrasound…
Abstract Number: 1107 • ACR Convergence 2025
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Laura Cappelli¹, Namrata Singh², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Pankti Reid¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Clifton Bingham¹⁵ and Ami Shah¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Washington, Bellevue, WA, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Chicago Medical Center, Chicago, IL, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins University, Baltimore, MD, ¹⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Large, multi-center efforts are needed to optimally study rheumatic immune-related adverse events (rh-irAEs) from immune checkpoint inhibitor (ICI) use. We aimed to characterize the…
Abstract Number: 0653 • ACR Convergence 2025
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
May-Linda Lepage¹, Patrick Nolain¹, Céline Cottereaux¹, Emilie Lagoutte¹, Justine Dao¹, Adrien Cosson¹, Laetitia Furio¹, Willem Hettema², Chantal Tasset³, Roland Blanqué¹, Isabelle Parent¹ and René Galien¹, ¹Galapagos SASU, Paris, France, ²Galapagos B.V., Leiden, Netherlands, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…
Abstract Number: 0439 • ACR Convergence 2025
Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
Blanche QUERE¹, Grégoire CORMIER², LE GOFF Benoit³ and Adrien LE PLUART⁴, ¹CHU de Nantes, Nantes, Pays de la Loire, France, ²Centre Hospitalier département de Vendée, La Roche Sur Yon, France, ³CHU Nantes, Nantes, France, ⁴CHU Nantes, Nantes, Pays de la Loire, France
Background/Purpose: Despite advances in therapeutic strategies, a subset of patients with rheumatoid arthritis (RA) continues to experience persistent symptoms. In 2022, the EULAR proposed a…
Abstract Number: 0127 • ACR Convergence 2025
Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
Wenying Liang¹, Qinmengge Li², Jacqueline Madison¹, Ran Jing¹, Emily Chong¹, Yiran Shen¹, Rachael Bogle³, Srilakshmi Yalavarthi¹, Cyrus Sarosh⁴, Ajay Tambralli¹, Yu (Ray) Zuo¹, Johann Gudjonsson¹, Hui Shi⁵, Pei-Suen Tsou¹, Alex Tsoi³ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Temperance, MI, ⁵Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study…

« Previous Page
1
…
5
6
7
8
9
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].